Progressive multifocal leukencephalopathy and cerebral toxoplasmosis in a patient with CLL.
Desmond
Ronan
R
Molecular Hematopoesis Section, Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA. ronandesmond@ireland.com
Lynch
Karen
K
Gleeson
Mary
M
Farrell
Michael
M
Murphy
Philip
P
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D016867:Immunocompromised Host; D007577:JC Virus / Q000302:isolation & purification / Q000502:physiology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D007968:Leukoencephalopathy, Progressive Multifocal / Q000209:etiology* / Q000473:pathology / Q000821:virology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016781:Toxoplasmosis, Cerebral / Q000209:etiology* / Q000473:pathology; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine